Cancer patients in crisis: responding to urgent needs

Royal Medical University (RCP) / Royal Radiological Association (RCR) working group was established in 2010 to study the experience of cancer patients with acute discomfort and urgent advice and advice, Identify disability to medical care and consider how to point out patient experience and care outcome

This study is being conducted in collaboration with a wide range of clinical specialties and representatives of patients and caregivers of the expert group. It has been developed with important national acute oncology, emergency medical and hospice care, and changes in hospitalization pathways. Many of the findings and conclusions of this report support and support the goals of these initiatives, but the report will broaden the background of all care settings, impact the quality of care, reduce opportunities to reduce patient risk We emphasize. Recommendations are as follows.

Medical professionals in all fields encounter the responsibility of acute uncomfortable cancer patients under all circumstances and share their responsibilities

Person in charge of development and development of labor force including undergraduate course and graduate course

Representatives of patients and caregivers express their support and support to promote greater patient involvement in future emergency response plans

In particular, working groups are aware of the vision and widespread impact of acute oncology measures. While the current financial environment may continue to limit the progress of full implementation, these measures promote important improvements in identifying and managing certain cancer emergencies, including acute and serious complications of cancer treatment There is no doubt that it is doing. Better staff will get easier access to oncologist advice and direct input from early oncologists, this will lead to a clearer way.

Despite recent developments in the development of cancer immunotherapy, only a small percentage of patients respond normally to these. Predictive markers for response to disease processes and immunotherapy are urgently needed. In order to fulfill this need, researchers at the Tisch Cancer Institute (TCI) at Icahn Medical College of Mount Sinai used only one tumor slice to analyze multiple tissue markers to better understand local development We developed a new way to do. This new technique, termed MICS for multiple immunohistochemical continuous staining on an immune response single slide, helps characterize human cells involved in the immune response in tissue sites before and after immunotherapy treatment . This study, published today in the Science Scienceology journal, may help identify new biomarkers to predict patient outcomes.

The first thing you need to know about researchers working on cancer immunotherapy is that each of them seems to have several patients who respond very well. It is no doubt that Steven Rosenberg of the National Cancer Institute will receive such an award. In 1984, he treated a woman named Linda Taylor with metastatic melanoma (invasive skin cancer with a survival rate of less than 10% after 10 years). Taylor is the first patient who undergo debilitating treatment and is the first successful patient. Within a few months her tumor disappears and she is still alive and healthy today. Rosenberg, the keynote speaker at the conference, reports that his latest treatment plan is not as difficult as a patient, and 20% of patients experience "complete and sustained relief." This is comparable to many of the immunotherapies currently being studied.